Trial Profile
Tolerance Induction Following Human Renal Transplantation Using Treatment With a Humanized Monoclonal Antibody Against CD52 (Campath-1H) [alemtuzumab]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Gusperimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Jul 2008 New trial record.